Award
NIH Reporter #11604355
Aggressive antipyretics for neuroprotection and mortality reduction in CNS malaria: A Randomized-Controlled Trial
Recipient
UNIVERSITY OF ROCHESTER
Award Amount
$12,160.00
Ceiling
$12,160.00
Awarded
September 10, 2026
Identifier
11604355
A phase III clinical trial funded to assess aggressive antipyretic therapy's effectiveness in reducing mortality and neurological issues in children with CNS malaria across multiple African sites.
Description
This project involves a phase III clinical trial to evaluate the efficacy of aggressive antipyretic therapy in reducing mortality and neurological morbidity in children with CNS malaria. The study will be conducted across multiple sites in Malawi, Zambia, and the Democratic Republic of Congo, with logistical and capacity-building activities planned in the Democratic Republic of Congo. The trial will compare maximal dose ibuprofen and acetaminophen versus standard care, with primary outcomes including time to death, neurodisability, or epilepsy.